Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC)

被引:16
|
作者
Hayes, S
Dunne, A [1 ]
Smart, T
Davis, J
机构
[1] Univ Coll Dublin, Dept Stat, Dublin 4, Ireland
[2] Pfizer Global Res & Dev, Sandwich, Kent, England
关键词
dissolution specifications; in vivo-in uitro correlation (IVIVC); bioequivalence; optimization;
D O I
10.1002/jps.10552
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This article considers the in vivo significance attached to in vitro dissolution testing. Almost invariably, the in vitro dissolution test is interpreted in terms of bioequivalence. The literature that describes methods for setting in vitro dissolution specifications is reviewed. The most common interpretation of these specifications is a deterministic one, that is, those batches passing the dissolution specifications would be bioequivalent with the reference if tested in vivo and those failing the dissolution specifications would not be bioequivalent if tested in vivo. Due to random variation, the deterministic interpretation is not appropriate. Instead, we need to consider the conditional probability that a batch that has passed the in vitro dissolution test would demonstrate bioequivalence if tested in vivo, and that a batch known to have failed the in vitro dissolution test would demonstrate bioinequivalence if tested in vivo. One way to estimate these probabilities is by means of a simulated experiment in which the production and testing (in vivo and in vitro) of a large number of batches is computer simulated. Such a simulation can only be performed if the relationship between the in vitro dissolution characteristics and the in vivo performance of the product has been modeled. These models are generally referred to as in vivo-in vitro correlations (IVIVC). The results of one such experiment are described. The above-mentioned conditional probabilities are shown to depend on the choice of dissolution specifications. This result leads to the notion of optimal dissolution specifications. However, both of the conditional probabilities cannot be maximized simultaneously. The probability of making a correct decision on the basis of the in vitro dissolution test is introduced as a possible optimality criterion. This probability is a linear combination of the two conditional probabilities of interest. Using this criterion, the optimal dissolution specifications can be found by searching over the multidimensional space defined by the half width of each interval used in the specifications to find the combination that maximizes this probability. This process is demonstrated using the Nelder-Mead search routine. The choice of dissolution specifications has profound implications for the routine production of the product because if the specifications were very narrow the probability of a batch passing would be low, resulting in a low hit rate. The same computer program used to perform the simulation experiment can be used to estimate the hit rate. Furthermore, it can be used to explore the magnitude of changes required in the parameters describing the test product (particularly variability) to increase a low hit rate to an acceptable level. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:571 / 581
页数:11
相关论文
共 50 条
  • [11] Physiologically Relevant In Vitro-In Vivo Correlation (IVIVC) Approach for Sildenafil with Site-Dependent Dissolution
    Kim, Tae Hwan
    Shin, Soyoung
    Jeong, Seok Won
    Lee, Jong Bong
    Shin, Beom Soo
    PHARMACEUTICS, 2019, 11 (06):
  • [12] IVIVC: Methods and applications in modified-release product development
    Rettig, Harald
    Mysicka, Jana
    DISSOLUTION TECHNOLOGIES, 2008, 15 (01): : 6 - 8
  • [13] Evaluating In Vivo-In Vitro Correlation Using a Bayesian Approach
    Junshan Qiu
    Marilyn Martinez
    Ram Tiwari
    The AAPS Journal, 2016, 18 : 619 - 634
  • [14] Physiologically relevant model to establish the in vivo-in vitro correlation for etamsylate controlled release matrix tablets
    Hedaya, Mohsen A.
    El-Masry, Soha M.
    Helmy, Sally A.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 66
  • [15] Evaluating In Vivo-In Vitro Correlation Using a Bayesian Approach
    Qiu, Junshan
    Martinez, Marilyn
    Tiwari, Ram
    AAPS JOURNAL, 2016, 18 (03): : 619 - 634
  • [16] In Vivo–In Vitro Correlation (IVIVC) Modeling Incorporating a Convolution Step
    T. O'Hara
    S. Hayes
    J. Davis
    J. Devane
    T. Smart
    A. Dunne
    Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28 : 277 - 298
  • [17] Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres
    Zolnik, Banu S.
    Burgess, Diane J.
    JOURNAL OF CONTROLLED RELEASE, 2008, 127 (02) : 137 - 145
  • [18] IN-VITRO IN-VIVO CORRELATION OF A MODIFIED-RELEASE ORAL FORM OF KETOTIFEN - IN-VITRO DISSOLUTION RATE SPECIFICATION
    HUMBERT, H
    CABIAC, MD
    BOSSHARDT, H
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (02) : 131 - 136
  • [19] Lidocaine Transdermal Patch: Pharmacokinetic Modeling and In Vitro–In Vivo Correlation (IVIVC)
    Phani Krishna Kondamudi
    Phani Prasanth Tirumalasetty
    Rajkumar Malayandi
    Srinivas Mutalik
    Raviraj Pillai
    AAPS PharmSciTech, 2016, 17 : 588 - 596
  • [20] Development and Validation of In Vitro-In Vivo Correlation (IVIVC) Model for Microparticulate Lornoxicam Loaded Controlled Release Tablet
    Shah, Pervaiz Akhtar
    Syed, Haroon Khalid
    Pervaiz, Areeba
    Gohar, Umar Farooq
    Saleem, Muhammad
    Iqbal, Muhammad Shahid
    Bin Liew, Kai
    Khan, Salah-Ud-Din
    Al-Saikhan, Fahad, I
    LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (02): : 370 - 377